IL6(白细胞介素6)是一种多功能细胞因子,属于白细胞介素家族,在免疫调节、炎症反应、造血和代谢过程中发挥核心作用。它主要由T细胞、巨噬细胞、内皮细胞和脂肪细胞产生,通过结合IL6受体(IL6R)和gp130信号转导蛋白激活JAK-STAT、MAPK和PI3K通路,影响靶细胞的增殖、分化和功能。IL6在急性炎症中起保护作用,促进肝细胞产生急性期蛋白(如C反应蛋白)和发热反应,同时刺激B细胞分化为浆细胞以增强抗体产生。然而,IL6的持续过表达与多种慢性炎症性疾病和自身免疫疾病相关,如类风湿性关节炎、克罗恩病和 Castleman病,还参与某些癌症(如多发性骨髓瘤)的发展,促进肿瘤细胞增殖和血管生成。IL6基因突变可能导致异常信号传导,例如IL6受体增益性突变与幼年特发性关节炎相关,而功能丧失突变可能增加感染风险。IL6过表达会加剧炎症反应和组织损伤,而降低表达可能削弱免疫防御但减轻炎症性疾病症状。IL6属于白细胞介素家族,该家族成员均为细胞因子,主要调节免疫细胞间的通讯和炎症反应。针对IL6或其受体的单克隆抗体(如托珠单抗)已用于治疗类风湿性关节炎和细胞因子风暴(如COVID-19重症病例),体现了其作为治疗靶点的重要性。
None
无
IL6基因(以及对应的蛋白质)的细胞分布位置:
IL6基因的本体(GO)信息:
| 名称 |
|---|
| 4630 Jak-STAT signaling pathway [PATH:hsa04630] |
| 4668 TNF signaling pathway [PATH:hsa04668] |
| 4066 HIF-1 signaling pathway [PATH:hsa04066] |
| 4068 FoxO signaling pathway [PATH:hsa04068] |
| 4151 PI3K-Akt signaling pathway [PATH:hsa04151] |
| 4060 Cytokine-cytokine receptor interaction [PATH:hsa04060] |
| 4640 Hematopoietic cell lineage [PATH:hsa04640] |
| 4620 Toll-like receptor signaling pathway [PATH:hsa04620] |
| 4621 NOD-like receptor signaling pathway [PATH:hsa04621] |
| 4623 Cytosolic DNA-sensing pathway [PATH:hsa04623] |
| 4672 Intestinal immune network for IgA production [PATH:hsa04672] |
| 5200 Pathways in cancer [PATH:hsa05200] |
| 5202 Transcriptional misregulation in cancers [PATH:hsa05202] |
| 5323 Rheumatoid arthritis [PATH:hsa05323] |
| 5321 Inflammatiory bowel disease (IBD) [PATH:hsa05321] |
| 5332 Graft-versus-host disease [PATH:hsa05332] |
| 5020 Prion diseases [PATH:hsa05020] |
| 5410 Hypertrophic cardiomyopathy (HCM) [PATH:hsa05410] |
| 4932 Non-alcoholic fatty liver disease (NAFLD) [PATH:hsa04932] |
| 5132 Salmonella infection [PATH:hsa05132] |
| 5133 Pertussis [PATH:hsa05133] |
| 5134 Legionellosis [PATH:hsa05134] |
| 5152 Tuberculosis [PATH:hsa05152] |
| 5166 HTLV-I infection [PATH:hsa05166] |
| 5162 Measles [PATH:hsa05162] |
| 5164 Influenza A [PATH:hsa05164] |
| 5161 Hepatitis B [PATH:hsa05161] |
| 5168 Herpes simplex infection [PATH:hsa05168] |
| 5146 Amoebiasis [PATH:hsa05146] |
| 5144 Malaria [PATH:hsa05144] |
| 5142 Chagas disease (American trypanosomiasis) [PATH:hsa05142] |
| 5143 African trypanosomiasis [PATH:hsa05143] |
| 名称 |
|---|
| Activated TLR4 signalling |
| ARMS-mediated activation |
| Axon guidance |
| Cellular responses to stress |
| Cellular Senescence |
| Cytokine Signaling in Immune system |
| DAP12 interactions |
| DAP12 signaling |
| Developmental Biology |
| Downstream signal transduction |
| Downstream signaling of activated FGFR1 |
| Downstream signaling of activated FGFR2 |
| Downstream signaling of activated FGFR3 |
| Downstream signaling of activated FGFR4 |
| ERK activation |
| ERK1 activation |
| ERK2 activation |
| Fc epsilon receptor (FCERI) signaling |
| FCERI mediated MAPK activation |
| FRS-mediated FGFR1 signaling |
| FRS-mediated FGFR2 signaling |
| FRS-mediated FGFR3 signaling |
| Frs2-mediated activation |
| FRS2-mediated FGFR4 signaling |
| Gastrin-CREB signalling pathway via PKC and MAPK |
| GRB2 events in EGFR signaling |
| GRB2 events in ERBB2 signaling |
| IGF1R signaling cascade |
| Immune System |
| Innate Immune System |
| Insulin receptor signalling cascade |
| Interleukin-2 signaling |
| Interleukin-6 signaling |
| IRS-mediated signalling |
| IRS-related events |
| IRS-related events triggered by IGF1R |
| MAP kinase activation in TLR cascade |
| MyD88 cascade initiated on plasma membrane |
| MyD88 dependent cascade initiated on endosome |
| MyD88-independent TLR3/TLR4 cascade |
| MyD88:Mal cascade initiated on plasma membrane |
| NCAM signaling for neurite out-growth |
| NGF signalling via TRKA from the plasma membrane |
| Prolonged ERK activation events |
| RAF/MAP kinase cascade |
| Senescence-Associated Secretory Phenotype (SASP) |
| SHC-mediated signalling |
| SHC-related events |
| SHC-related events triggered by IGF1R |
| SHC1 events in EGFR signaling |
| SHC1 events in ERBB2 signaling |
| SHC1 events in ERBB4 signaling |
| Signal Transduction |
| Signaling by EGFR |
| Signaling by ERBB2 |
| Signaling by ERBB4 |
| Signaling by FGFR |
| Signaling by FGFR1 |
| Signaling by FGFR2 |
| Signaling by FGFR3 |
| Signaling by FGFR4 |
| Signaling by GPCR |
| Signaling by Insulin receptor |
| Signaling by Interleukins |
| Signaling by Leptin |
| Signaling by PDGF |
| Signaling by SCF-KIT |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) |
| Signaling by VEGF |
| Signalling by NGF |
| Signalling to ERKs |
| Signalling to p38 via RIT and RIN |
| Signalling to RAS |
| SOS-mediated signalling |
| Toll Like Receptor 10 (TLR10) Cascade |
| Toll Like Receptor 2 (TLR2) Cascade |
| Toll Like Receptor 3 (TLR3) Cascade |
| Toll Like Receptor 4 (TLR4) Cascade |
| Toll Like Receptor 5 (TLR5) Cascade |
| Toll Like Receptor 7/8 (TLR7/8) Cascade |
| Toll Like Receptor 9 (TLR9) Cascade |
| Toll Like Receptor TLR1:TLR2 Cascade |
| Toll Like Receptor TLR6:TLR2 Cascade |
| Toll-Like Receptors Cascades |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation |
| TRAF6 Mediated Induction of proinflammatory cytokines |
| TRIF-mediated TLR3/TLR4 signaling |
| VEGFA-VEGFR2 Pathway |
| VEGFR2 mediated cell proliferation |
| 疾病名称 | 关系值 | NofPmids | NofSnps | 来源 |
| Diabetes Mellitus, Non-Insulin-Dependent | 0.420661594 | 76 | 2 | BeFree_CLINVAR_CTD_human_GAD_LHGDN_RGD |
| Obesity | 0.289229902 | 116 | 5 | BeFree_CTD_human_GAD_RGD |
| Rheumatoid Arthritis, Systemic Juvenile | 0.240271442 | 1 | 0 | BeFree_CTD_human_ORPHANET |
| Multiple Myeloma | 0.225615597 | 239 | 1 | BeFree_CTD_human_GAD_LHGDN |
| Inflammation | 0.219070452 | 70 | 0 | CTD_human_GAD_LHGDN |
| Rheumatoid Arthritis | 0.212623944 | 187 | 5 | BeFree_CTD_human_GAD_LHGDN |
| Heart failure | 0.205081451 | 15 | 0 | BeFree_CTD_human_GAD_RGD |
| Depressive disorder | 0.203800186 | 15 | 0 | BeFree_CTD_human_RGD |
| Reperfusion Injury | 0.202367032 | 7 | 0 | CTD_human_GAD_RGD |
| Diabetes Mellitus, Experimental | 0.2 | 4 | 0 | CTD_human_RGD |
山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼
电话: 0531-88819269
E-mail: product@genelibs.com
关注微信订阅号,实时查看信息,关注医学生物学动态。